SoftServe Offers Complimentary Assessment for In-Store Social Distancing Solution
28.7.2020 14:00:00 EEST | Business Wire | Press release
SoftServe, a leading digital authority and consulting company, is offering a complimentary assessment through September 30, 2020 for its In-Store Social Distancing Solution, a cloud-based computer vision and mobile app solution that offers retailers a 360-degree customer view through AI-powered advanced analytics to support value-led decision making through actionable insights. This solution enables stores to provide a secure shopping environment for customers and employees while remaining compliant with government mandated social distancing regulations, as well as track customer engagement to understand future buying dynamics and optimize store layouts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200728005019/en/
SoftServe's In-Store Social Distancing Solution mobile interface. (Photo: Business Wire)
Computer vision is a form of artificial intelligence (AI) that trains computers to interpret and understand digital images from cameras and videos. Computers can ‘learn’ to accurately identify and classify objects, and then react to and report on what they ‘see’. It’s a rapidly growing platform for real-time store management and enhanced operations. By 2021, 40% of retailers will implement computer vision in their customer service and support workflow, and vendors employing computer vision in retail will see a 20% lift in conversion.1
“SoftServe’s in-store social distancing solution is bridging a critical gap for retailers, ensuring a safe shopping environment through the COVID-19 pandemic while providing a valuable long-term solution for continual security, future growth, and consumer engagement,” said Valentyn Kropov, VP, client success at SoftServe. “Our solution works with your existing in-store equipment and can be ‘retrained’ around future scenarios, giving you a foundation on which to optimize store operations and customer experience for years to come.”
Ensure Customer and Employee Safety and Social Distancing Regulatory Compliance
- Mask and Temperature Detection—detect if patrons are wearing masks and scan customers’ temperatures with an infrared thermometer upon entry.
- Manage Store Capacity—count the number of patrons entering and exiting the store and provide entry permission alerts and QR code vouchers through a mobile app.
- Avoid Physical Lines—track designated distance between queued customers, provide department wait times and information through digital signage, and allow patrons to reserve spots in line.
Identify and Understand Customers’ Buying Dynamics
- Real-Time Data Processing—get actionable insights in the moment with a self-learning system that fully automates data collection.
- In-Store Customer Tracking—understand your customers’ in-store movements and product engagement better with demographics and heatmap analysis.
- Create More Immersive Shopping Experiences—learn customer interaction points and deploy AI-driven dynamic in-store advertisements. Use location analytics to optimize store layout and product positioning around customer preferences.
SoftServe’s In-Store Social Distancing Solution integrates with a store’s existing CCTV infrastructure and software platforms and can be rapidly deployed to be up and running in a couple of weeks. It’s designed to be scalable for hundreds of stores, yet is customizable around the specific business needs of each individual store.
Book your complimentary assessment and demo through the end of September today. Contact RetailDemo@softserveinc.com for a timely evaluation of your store environment to identify the most cost-efficient solution.
1 Nick Ingelbrecht, Anthony Bradley “Emerging Technologies: Top Advanced Computer Vision Use Cases for Retail”, Gartner, April 23, 2020
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience is built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website, blog, LinkedIn, Facebook, and Twitter pages.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005019/en/
Contact information
Paul Jones
Senior Manager, Analyst and Public Relations
pjone@softserveinc.com
512-796-7358
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
